Previous 10 | Next 10 |
Gainers: TrovaGene (NASDAQ: TROV ) +65% . Biogen (NASDAQ: BIIB ) +29% . Stamps.com (NASDAQ: STMP ) +24% . Teekay Corporation (NYSE: TK ) +22% . Cision (NYSE: CISN ) +19% . Teekay LNG Partners (NYSE: TGP ) +17% . Obalon Therapeutics (NASDAQ: OBLN ) +14%. Athenex (NASDAQ: ...
Nano cap Trovagene ( TROV +79% ) is up on a healthy 38x surge in volume in response to positive preliminary data from a Phase 1b/2 clinical trial evaluating lead asset onvansertib, combined with chemo regimen FOLFIRI and Roche's Avastin (bevacizumab), for the second-line treatment of p...
TrovaGene (NASDAQ: TROV ) +56% on positive response to treatment in phase 1b/2 trial of onvansertib in patients with KRAS-mutated metastatic colorectal cancer. More news on: TrovaGene, Inc., Biogen Inc., Stamps.com Inc., Stocks on the move, Read more ...
SAN DIEGO , Oct. 22, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV) , a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis) for the treatment of various cancers including prostate, colorectal ...
SAN DIEGO , Oct. 2, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis) for the treatment of various cancers including breast, prostate, colo...
SAN DIEGO , Oct. 1, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis) for the treatment of various cancers including prostate, colorec...
TROV stock is one of the biggest biotech stock gainers this morning after TrovaGene Inc (NASDAQ:TROV) reported positive results from its Phase 1b/2 study of onvansertib. Key Details Companies in the therapeutics space strive for producing treatments for some of the most difficult health...
Trovagene ( TROV +14.3% ) announces that results from the Phase 1b/2 study of onvansertib in patients with relapsed/refractory acute myeloid leukemia (AML) were presented at the 2019 European Society for Medical Oncology Conference in Barcelona, Spain, on Saturday, September 28th. More...
Dova Pharmaceuticals (NASDAQ: DOVA ) +39% on being acquired by Sobi. More news on: Dova Pharmaceuticals, Inc., Bed Bath & Beyond Inc., ImmunoGen, Inc., Stocks on the move, Read more ...
SAN DIEGO , Sept. 30, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV) , a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis), for the treatment of various cancers including leukemia, pros...
News, Short Squeeze, Breakout and More Instantly...
SAN DIEGO , May 7, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including colorectal cancer, prostate cancer and leukemia, today a...
SAN DIEGO , May 6, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company developing its drug, onvansertib, to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, Zytiga&...
SAN DIEGO , April 28, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including colorectal cancer, prostate cancer and leukemia, ...